Blocking interleukin 12 may protect insulin-producing cells and blood vessels in type 2 diabetes.
Official title: Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes
Funded at Old Dominion University · NIH-11123521 · Data updated 2026-11-12
This study is looking at how a substance called IL-12 affects people with type 2 diabetes, specifically how it might harm insulin-producing cells and blood vessels, and it hopes to find ways to block IL-12 to help protect these important parts of the body and reduce diabetes-related health issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Old Dominion University NIH-funded |
| Lab location | 1 site (Norfolk, United States) |
| Project start | August 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $73,063 |
| NIH project number | 6R01HL150014-05 |
| Project ID | NIH-11123521 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with type 2 diabetes who are experiencing complications related to beta cell failure and microvascular dysfunction.
✕Less likely to help
Patients without type 2 diabetes or those whose condition is not related to beta cell or microvascular issues may not benefit from this research.
What this research studies
This research investigates the role of interleukin 12 (IL-12) in type 2 diabetes and its impact on insulin-producing beta cells and blood vessel function. The study aims to understand how inhibiting IL-12 can prevent damage to these cells and reduce complications associated with diabetes, such as heart disease and kidney damage. By exploring the mechanisms behind IL-12's effects, the research seeks to identify new treatment targets that could improve overall health for patients with type 2 diabetes.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that protect vital cells and improve health outcomes for individuals with type 2 diabetes.
How similar studies have gone: While the specific approach of targeting IL-12 in type 2 diabetes is novel, similar research has shown that targeting inflammatory cytokines can lead to improvements in related conditions.
Where this research is happening
-
Old Dominion University
Norfolk, United States Active
Researchers
- Principal investigator: Matrougui, Khalid — Old Dominion University
- Study coordinator: Matrougui, Khalid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.